PL2246427T3 - Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie - Google Patents

Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie

Info

Publication number
PL2246427T3
PL2246427T3 PL09707511T PL09707511T PL2246427T3 PL 2246427 T3 PL2246427 T3 PL 2246427T3 PL 09707511 T PL09707511 T PL 09707511T PL 09707511 T PL09707511 T PL 09707511T PL 2246427 T3 PL2246427 T3 PL 2246427T3
Authority
PL
Poland
Prior art keywords
oligomers
amyloid beta
antibodies capable
binding specifically
binding
Prior art date
Application number
PL09707511T
Other languages
English (en)
Inventor
Etsuro Matsubara
Masao Shibata
Tatsuki Yokoseki
Original Assignee
Immunas Pharma, Inc.
National Center For Geriatrics And Gerontology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunas Pharma, Inc., National Center For Geriatrics And Gerontology filed Critical Immunas Pharma, Inc.
Publication of PL2246427T3 publication Critical patent/PL2246427T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL09707511T 2008-02-08 2009-02-06 Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie PL2246427T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008028386 2008-02-08
US8554508P 2008-08-01 2008-08-01
JP2008201058 2008-08-04
EP09707511.3A EP2246427B1 (en) 2008-02-08 2009-02-06 Antibodies capable of binding specifically to amyloid beta-oligomers, and use thereof

Publications (1)

Publication Number Publication Date
PL2246427T3 true PL2246427T3 (pl) 2017-06-30

Family

ID=40952248

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09707511T PL2246427T3 (pl) 2008-02-08 2009-02-06 Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie

Country Status (14)

Country Link
US (3) US8378081B2 (pl)
EP (2) EP2246427B1 (pl)
JP (2) JP5113853B2 (pl)
KR (1) KR101616136B1 (pl)
CN (2) CN102124105A (pl)
AU (2) AU2009211635B2 (pl)
CA (1) CA2714413C (pl)
DK (1) DK2246427T3 (pl)
ES (1) ES2617604T3 (pl)
HU (1) HUE031944T2 (pl)
PL (1) PL2246427T3 (pl)
PT (1) PT2246427T (pl)
SG (1) SG188116A1 (pl)
WO (1) WO2009099176A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10277519B2 (en) * 2006-01-31 2019-04-30 Silicon Laboratories Inc. Response time for a gateway connecting a lower bandwidth network with a higher speed network
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
PT2099826E (pt) * 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
AU2008204335B2 (en) * 2007-01-11 2013-06-13 Michael Bacher Diagnosis and treatment of Alzheimer's and other neurodementing diseases
US20100291071A1 (en) * 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
EP2210901A4 (en) * 2007-10-19 2012-04-25 Immunas Pharma Inc FOR THE SPECIFIC BINDING TO AN OLIGOMICALLY ABLE ANTIBODY AND ITS USE
EP2246427B1 (en) 2008-02-08 2016-11-30 Immunas Pharma, Inc. Antibodies capable of binding specifically to amyloid beta-oligomers, and use thereof
CA2730073A1 (en) * 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
WO2010119704A1 (en) 2009-04-17 2010-10-21 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
DK2462161T3 (en) 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
DK2462162T3 (en) 2009-08-06 2017-01-16 Immunas Pharma Inc Antibodies that specifically bind to A-beta oligomers and their use
WO2011016568A1 (ja) 2009-08-07 2011-02-10 協和発酵キリン株式会社 抗アミロイドβオリゴマーヒト化抗体
MX2012001708A (es) * 2009-08-07 2012-05-22 Kyowa Hakko Kirin Co Ltd Anticuerpo humanizado anti-oligomero de amiloide b.
US8795664B2 (en) * 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2012012257A2 (en) * 2010-07-19 2012-01-26 Virginia Commonwealth University BIVALENT MULTIFUNCTIONAL LIGANDS TARGETING Aβ OLIGOMERS AS TREATMENT FOR ALZHEIMER'S DISEASE
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
CA2867338A1 (en) * 2012-03-13 2013-09-19 Janssen Alzheimer Immunotherapy Oligomeric a.beta. in the diagnosis, prognosis, and monitoring of alzheimer's disease
DK3269736T3 (da) 2012-05-10 2020-01-13 Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin Konformationsspecifikke antistoffer mod oligomerer af amyloid beta
JP6092049B2 (ja) * 2013-08-28 2017-03-08 東芝ライフスタイル株式会社 撮像システム及び撮像装置
WO2015111430A1 (ja) 2014-01-21 2015-07-30 株式会社 島津製作所 Ａｐｐ切断型ペプチドの測定方法
EP4040157A1 (en) 2014-05-22 2022-08-10 Shimadzu Corporation Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof
US9732148B2 (en) * 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
GB2541003A (en) * 2015-08-05 2017-02-08 Kran Life Sciences Llp Neurodegenerative disorders
EP4424704A3 (en) 2015-09-16 2024-12-25 Shimadzu Corporation Multiplex biomarker for use in evaluation of state of accumulation of amyloid b in brain, and analysis method for said evaluation
WO2017120557A1 (en) * 2016-01-09 2017-07-13 Arbele Limited Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
JP2017132742A (ja) * 2016-01-29 2017-08-03 国立大学法人 大分大学 Ａβオリゴマー特異的抗体の新規薬理用途
CN107118260B (zh) * 2017-05-12 2020-10-16 中国科学院过程工程研究所 一种多肽及其组成的疫苗和应用
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
JP7289033B2 (ja) 2018-10-01 2023-06-09 徹 宮崎 神経変性疾患治療剤
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
US20220380454A1 (en) * 2019-06-28 2022-12-01 The Regents Of The University Of California Methods and compositions for treating alzheimer's disease
JP7370569B2 (ja) * 2019-08-07 2023-10-30 国立大学法人 大分大学 アミロイドβタンパク質オリゴマーと結合するヒト化抗体
GB201912008D0 (en) * 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
WO2021067628A2 (en) * 2019-10-01 2021-04-08 Beth Israel Deaconess Medical Center, Inc. Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
CA3226568A1 (en) * 2021-07-19 2023-01-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Mct11 antibodies to treat t cell functional exhaustion and enhance cancer immunotherapy
JP2024546046A (ja) * 2021-11-15 2024-12-17 アセンド バイオテクノロジー インク Ｔｒｅｍｌ１により誘導された免疫抑制を逆転させる方法
CN114605532B (zh) * 2022-05-07 2022-08-23 北京第一生物化学药业有限公司 抗β-淀粉样蛋白抗体及其用途
CN117088984B (zh) * 2022-05-11 2024-05-10 东莞市朋志生物科技有限公司 抗苯二氮卓抗体、检测苯二氮卓的试剂和试剂盒
CN116789818B (zh) * 2023-06-25 2024-01-26 东南大学 一种抗β淀粉样蛋白的单链抗体及应用
CN119306840B (zh) * 2024-11-06 2025-11-04 郑州伊美诺生物技术有限公司 嗜酸性粒细胞过氧化物酶的单克隆抗体及其应用
CN119798430B (zh) * 2025-02-08 2025-08-26 上海近则生物科技有限责任公司 一种结合Aβ寡聚体的抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
AUPR617901A0 (en) 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
JP4729717B2 (ja) 2001-08-03 2011-07-20 株式会社医学生物学研究所 ＧＭ１ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするＤＮＡ
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2010012004A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
EP1769002A1 (en) * 2004-07-02 2007-04-04 Northwestern University Monolocal antibodies that target pathological assemblies of amyloid beta; (abeta)
US20080044356A1 (en) 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
AU2005306997B2 (en) 2004-10-25 2012-07-05 Merck Sharp & Dohme Corp. Anti-ADDL antibodies and uses thereof
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
EP1853299A4 (en) 2005-01-14 2009-11-11 Univ California COMPOSITIONS AND METHODS FOR INHIBITING THE PRESENCE OF DRUGS AND DIAGNOSING OR TREATING DRUG-INDUCED DISEASES
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
MX2007010687A (es) 2005-03-05 2008-01-28 Abbott Gmbh & Co Kg Metodo de clasificacion, procedimiento para la purificacion de oligomeros a-beta no difundibles, anticuerpos selectivos contra dichos oligomeros a-beta no difundibles y un procedimiento para la fabricacion de dichos anticuerpos.
EP1921137A4 (en) 2005-06-21 2011-01-26 Med & Biological Lab Co Ltd ANTIBODIES WITH INHIBITOR EFFECT ON THE FORMATION OF AMYLOID FIBRILLES
EP1749839A1 (en) 2005-07-22 2007-02-07 Novoplant GmbH Antigen binding polypeptides against F4(K88) fimbriae
BRPI0709050B1 (pt) * 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
US20090232801A1 (en) 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US20100291071A1 (en) 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
EP2210901A4 (en) 2007-10-19 2012-04-25 Immunas Pharma Inc FOR THE SPECIFIC BINDING TO AN OLIGOMICALLY ABLE ANTIBODY AND ITS USE
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
EP2246427B1 (en) * 2008-02-08 2016-11-30 Immunas Pharma, Inc. Antibodies capable of binding specifically to amyloid beta-oligomers, and use thereof
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
WO2010119704A1 (en) 2009-04-17 2010-10-21 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
DK2462162T3 (en) 2009-08-06 2017-01-16 Immunas Pharma Inc Antibodies that specifically bind to A-beta oligomers and their use
DK2462161T3 (en) 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use

Also Published As

Publication number Publication date
HK1181789A1 (en) 2013-11-15
CN102124105A (zh) 2011-07-13
CN102936287B (zh) 2015-09-09
EP2246427A4 (en) 2012-04-25
US9090680B2 (en) 2015-07-28
CA2714413A1 (en) 2009-08-13
EP3121277A1 (en) 2017-01-25
JP5765857B2 (ja) 2015-08-19
US8378081B2 (en) 2013-02-19
AU2009211635A1 (en) 2009-08-13
WO2009099176A1 (ja) 2009-08-13
JPWO2009099176A1 (ja) 2011-05-26
CA2714413C (en) 2017-01-24
EP2246427A1 (en) 2010-11-03
PT2246427T (pt) 2017-03-03
HUE031944T2 (en) 2017-08-28
EP3121277B1 (en) 2018-04-11
KR20100113623A (ko) 2010-10-21
JP2013063976A (ja) 2013-04-11
US20130149316A1 (en) 2013-06-13
JP5113853B2 (ja) 2013-01-09
DK2246427T3 (da) 2017-02-20
AU2014224074A1 (en) 2014-10-02
US20100028357A1 (en) 2010-02-04
AU2009211635B2 (en) 2014-06-26
SG188116A1 (en) 2013-03-28
ES2617604T3 (es) 2017-06-19
KR101616136B1 (ko) 2016-04-27
EP2246427B1 (en) 2016-11-30
US20110097319A1 (en) 2011-04-28
CN102936287A (zh) 2013-02-20

Similar Documents

Publication Publication Date Title
PT2246427T (pt) Anticorpos capazes de se ligar especificamente a oligómeros beta amilóides e a sua utilização
IL257290A (en) Antibodies to il 6 and their use
IL261019B (en) Antibodies to 6-il and their use
ZA201003496B (en) Monoclonal antibody capable of binding to anexelekto,and use thereof
IL248723B (en) Specific antibodies against the bcr complex and methods of using them
SI2373691T1 (sl) Protitelesa proti FXI in postopki uporabe
SG10201801945TA (en) Specific binding proteins and uses thereof
IL230771A (en) Antibody from a person that binds pcsk9
IL232276A0 (en) Antibodies to 6-il and their uses
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
ZA201101651B (en) Anti-notch2 antibodies and methods of use
ZA201100058B (en) Prostaglandin e2 binding proteins and uses thereof
IL216731A (en) And antibodies against p95 – her2 and their uses
EP2504031A4 (en) ANTI-IL-6 ANTIBODIES AND THEIR USE
ZA201107555B (en) Anti-17f antibodies and methods of use thereof
SG10201609416XA (en) NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
PT2185719E (pt) Anticorpos anti-rantes e processos para a sua utilização
IL213353A0 (en) Anti-pd-l1 antibodies and their use to enhance t-cell function
GB0807018D0 (en) Antibodies and treatment